MARK ELAD enters SCINAI IMMUNOTHERAPEUTICS LTD. with 160.36M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 3/26/2026ACC: 0001178913-26-001750
Officer· Chief Operating Officer
Since Jan 2023
160.36M
Baseline shares
100% direct
160.36M
Direct ownership
1 position
13.46M
Derivative underlying
1 instrument
1
Security positions
All direct
Non-Derivative Holdings1
Ordinary shares, no par value per share ("Ordinary Shares")
DirectShares owned160.36M
Total
160.36M direct160.36M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Ordinary shares, no par value per share ("Ordinary Shares") | 160.36M | Direct |
| Total | 160.36M | 160.36M direct |
Derivative Holdings1
American Depositary Shares
DirectUnderlying security
Ordinary Shares
Underlying shares
13.46M
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Total
Underlying
13.46M
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| American Depositary Shares Direct | Ordinary Shares | — | — | 13.46M | N/A | |
| Total | 13.46M | 0.00 | ||||